ArticleCurrent microbiology2025
Potential Effects of Omega-3 Fatty Acids and Encapsulated Omega-3 Fatty Acids against Escherichia Coli and Bacillus Toyonensis.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Since foodborne bacterial illnesses are a serious problem, researchers are searching for substitutes that can prevent harmful bacteria and enhance probiotics. This study aims to investigate whether omega-3 fatty acids (ω3FAs) and encapsulated ω3FAs possess antibacterial properties against Escherichia coli O157 and Bacillus toyonensis PS-NRD5. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and time-kill kinetic assays were conducted to evaluate the antibacterial activity in a dose-dependent manner. Enzymatic assays were analysed to understand mechanism of bacterial eradication, with a focus on oxidative stress. Membrane disruption experiments were performed, and MALDI-TOF MS was utilized to analyse cleavage in lipopolysaccharide and peptidoglycan extracted from E. coli and B. toyonensis, respectively. ω3FAs were highly effective in rupturing bacterial membranes due to enzymatic and oxidative stress, ultimately causing bacterial death after 120 min of treatment. Both bacterial strains showed changes in membrane permeability. E. coli exhibited changes in the lipid A fragments of lipopolysaccharides, whereas B. toyonensis peptidoglycan remained unchanged. As an antibacterial agent, ω3FAs have the potential to control both E. coli and B. toyonensis. This research sheds light on the potential use of ω3FAs and Enω3FAs in public health and food safety.
Indexed as
Identifiers
41284023What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.